1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6211)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13088)
  2. Department of Medicine (13004)
  3. Center for Hematologic Malignancies (10395)
  4. GSK Faculty (4422)
  5. Adult Leukemia (3583)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (775)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (204)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (431)

More Publishers

Results (13088)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PRC2 inactivating mutations amplify cell death in response to DNMT1-targeted therapy through enhanced viral mimicry in malignant peripheral nerve sheath tumor
    Meeting Abstract

    Chi, P.; Patel, A. J.; Warda, S.; Maag, J. L. V.; Misra, R.; Miranda-Román, M. A.; Pachai, M. R.; Lee, C. J.; Li, D.; Wang, N.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Targeted sequencing of 2,138 bone and soft tissue sarcomas reveals commonly altered pathways, subtype-independent genetic clusters, and potential therapeutic targets
    Meeting Abstract

    Nacev, B. A.; Sanchez-Vega, F.; Smith, S.; Antonescu, C.; Rosenbaum, E.; Shi, H.; Tang, C.; Socci, N.; Rana, S.; Gularte-Merida, R.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil as the new standard for graft-versus-host disease (GVHD) prophylaxis in reduced intensity conditioning: Results from phase III BMT CTN 1703
    Meeting Abstract

    Holtan, S. G.; Hamadani, M.; Wu, J.; Al Malki, M. M.; Runaas, L.; Elmariah, H.; Rezvani, A. R.; Gooptu, M.; Larkin, K. T.; Shaffer, B. C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib
    Journal Article

    Mato, A. R.; Tang, B.; Azmi, S.; Yang, K.; Zhang, X.; Stern, J. C.; Hedrick, E.; Huang, J.; Sharman, J. P.
    Haematologica (2022)

    Fulltext@MSK | Save
  • Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
    Journal Article

    Salles, G.; Schuster, S. J.; Dreyling, M.; Fischer, L.; Kuruvilla, J.; Patten, P. E. M.; von Tresckow, B.; Smith, S. M.; Jiménez-Ubieto, A.; Davis, K. L.; more...
    Blood Advances (2022)

    Fulltext@MSK | Save
  • The role of allogeneic transplant for adult Ph(+) ALL in CR1 with complete molecular remission: A retrospective analysis
    Journal Article

    Ghobadi, A.; Slade, M.; Kantarjian, H.; Alvarenga, J.; Aldoss, I.; Mohammed, K. A.; Jabbour, E.; Faramand, R.; Shah, B. J.; Locke, F.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • The potential for technology to aid quantitative assessment in cutaneous T cell lymphoma
    Correspondence

    Gu, L.; Oh, Y.; Smith, M. P.; Kurtansky, N. R.; Horwitz, S.; Kahn, N.; Moskowitz, A.; Noor, S. J.; Myskowski, P.; Rotemberg, V.
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy
    Correspondence

    Nath, K.; Shekarkhand, T.; Salcedo, M.; Derkach, A.; Rueda, S.; Chansakul, A.; Hulcrantz, M.; Korde, N.; Shah, U. A.; Tan, C.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Point-of-care CAR T-cell therapy as salvage strategy for out-of-specification tisagenlecleucel
    Journal Article

    Fried, S.; Shouval, R.; Varda-Bloom, N.; Besser, M. J.; Yerushalmi, R.; Shem-Tov, N.; Danylesko, I.; Jacoby, E.; Teihman, S.; Itzhaki, O.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults
    Journal Article

    Politikos, I.; Lau, C.; Devlin, S. M.; Quach, S.; Lin, A.; Perales, M. A.; Shah, G. L.; Seo, S. K.; Papanicolaou, G. A.; Barker, J. N.
    Blood Advances (2022)

    Fulltext@MSK | Save